Top

Published in:

01-01-2012 | Editorial

The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma

Author: Scott A. Hundahl

Published in: Gastric Cancer | Issue 1/2012

Excerpt

In the current issue, Fujita, Kurokawa, Sugimoto et al. describe interim results of an interesting two-armed non-inferiority trial that was designed to justify the potential elimination of bursectomy (also known as “omentobursectomy”) from a standard D2 operation for advanced gastric cancer. This is probably one of the last purely surgical trials to be reported for advanced disease, given the currently established role for adjuvant therapy [1‐3]. The trial was prematurely halted as a result of the convincing S-1 Trial [3], which clearly demonstrated the value of adjuvant therapy in Asian patients following high-quality D2 resection. …

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.PubMedCrossRef

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRef

Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.PubMedCrossRef

Title: The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma
Author: Scott A. Hundahl
Publication date: 01-01-2012
Publisher: Springer Japan
Published in: Gastric Cancer / Issue 1/2012
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI: https://doi.org/10.1007/s10120-011-0121-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Discrepancies in histologic diagnoses of early gastric cancer between biopsy and endoscopic mucosal resection specimens

Evaluation of modified Estimation of Physiologic Ability and Surgical Stress in gastric carcinoma surgery

Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients

First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer

Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer

Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page